APRE NASDAQ
Aprea Therapeutics, Inc.
1W: -8.7%
1M: -15.2%
3M: -7.3%
YTD: -18.5%
1Y: -52.4%
3Y: -82.7%
5Y: -99.2%
$0.69
-0.03 (-3.94%)
Weekly Expected Move ±6.9%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$8.6M
52W Range0.548-1.69
Volume862,222
Avg Volume216,390
Beta1.63
Dividend—
Analyst Ratings
Company Info
3805 Old Easton Road
Boston, PA 18902
US
Boston, PA 18902
US
617-463-9385
About Aprea Therapeutics, Inc.
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
Latest News
Aprea Therapeutics to Present Updated Interim Phase 1 Data on WEE1 Inhibitor APR-1051 in an Oral Presentation at 38th EORTC-NCI-AACR Symposium
Aprea Therapeutics Announces Expansion of Intellectual Property Portfolio for Precision Oncology Programs
Aprea Therapeutics Announces Second Quarter 2026 Financial Results
Zymeworks Inc. (ZYME) Reports Q2 Loss, Beats Revenue Estimates
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Grissinger Michael | A-Award | 3,135 | — | 2026-06-16 |
| Grissinger Michael | A-Award | 12,555 | $0.73 | 2026-06-16 |
| Gruia Gabriela | A-Award | 3,135 | — | 2026-06-16 |
| Gruia Gabriela | A-Award | 12,555 | $0.73 | 2026-06-16 |
| Peters Richard | A-Award | 3,135 | — | 2026-06-16 |